Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer.
| Autor: | Huy TL; Department of Oncology, Hanoi Medical University Hospital, Hanoi, Vietnam., Bui MH; Tuberculosis and Lung Disease Department, Hanoi Medical University, Hanoi, Vietnam.; Scientific Research & International Cooperation Department, Hanoi Medical University Hospital, Hanoi, Vietnam., Dinh TC; Department of Human and Animal Physiology, Faculty of Biology, Hanoi National University of Education, Hanoi, Vietnam., Xuyen HTH; Center for Development of Curriculum and Human Resource in Health, Hanoi Medical University, Hanoi. Vietnam. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Open access Macedonian journal of medical sciences [Open Access Maced J Med Sci] 2019 Dec 10; Vol. 7 (24), pp. 4244-4249. Date of Electronic Publication: 2019 Dec 10 (Print Publication: 2019). |
| DOI: | 10.3889/oamjms.2019.368 |
| Abstrakt: | Background: In recent times, scientists have found new treatments for colorectal cancer patients. Aim: The study is to evaluate the efficacy and toxicity of triplet combination chemotherapy of 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) for patients with metastatic colorectal cancer in stage IV. Methods: Uncontrolled clinical trial carried on 39 stage IV colorectal cancer patients. Results: The overall response rate of the treatment was 79.4%. The average progression-free survival was 13.4 ± 9 months. The overall survival rate at 12th month and 24th month were 90% and 76%, respectively. The proportion of granulocytopenia was 48.9%, no grade 3 or 4. Side effect beyond hematology was most seen in hepatic toxicity with 52.5%, mainly at grade 1. Vomiting was 18.3%, all at grade 1. Other adverse event was very low at percentage. Conclusions: The triplet combination FOLFOXIRI chemotherapy improves the outcome of patients with metastatic colorectal cancer regarding rate of response, overall survival rate and progression-free survival, and the level of toxicity was acceptable. (Copyright: © 2019 Trinh Le Huy, My Hanh Bui, Toi Chu Dinh, Hoang Thi Hong Xuyen.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|